Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957252 · ClinicalTrials.gov registry record
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by Nanostics.
- Active
- Registry status
- 2,800
- Enrollment target
- 3
- Study locations
NCT03957252: Active study of Prostate Cancer, sponsored by Nanostics.
NCT03957252 is a study of Prostate Cancer that is active but no longer recruiting, run by Nanostics. The registered enrollment target is 2,800 participants, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (363% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03957252, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Nanostics.
- ACTIVE NOT RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to determine the accuracy of blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater or equal to 3 ng/mL.
Primary Outcome
Training Phase: Processed clinical features of each patient will be analyzed using machine learning to predict clinically significant prostate cancer, with the output being the ClarityDX Prostate Risk Score. Validation Phase: The models created during the Training Phase will be locked down and then used to determine the probability of approximately 1,400 patients in the investigational Validation Phase having clinically significant prostate cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood test: ClarityDX Prostate
Study Locations (3)
Alberta
- Prostate Cancer Centre - Calgary
- Kipnes Urology Centre - Edmonton
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2027-03 |
What the registry record for NCT03957252 still lists
NCT03957252 is an observational study that tracks outcomes without assigning an intervention. Its 2,800 participants enrollment target places it among the larger protocols in the corpus, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (363% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood test: ClarityDX Prostate is the first listed.
NCT03957252 reports a single indexed study location in Alberta, Maryland.
Frequently Asked Questions
What is clinical trial NCT03957252 about?
NCT03957252 is a clinical study titled "Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer". This study is designed to determine the accuracy of blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater or equal to 3 ng/mL.
What is the current status of trial NCT03957252?
This trial is currently active not recruiting. The enrollment target is 2,800 participants. The study started on 2019-06-06. Estimated completion is 2027-03.
What conditions does trial NCT03957252 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03957252?
The interventions under investigation include: Blood test: ClarityDX Prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03957252?
This trial is sponsored by Nanostics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03957252 being conducted?
This trial has 3 study locations across Maryland, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03957252's enrollment target sits among peer trials
2,800 20th of 735 higher than 716 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI